Investigation Launched into Kezar's Transaction with Aurinia
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 07 2026
0mins
Should l Buy KZR?
Source: Globenewswire
- Shareholder Rights Investigation: Ademi LLP is investigating Kezar (NASDAQ: KZR) for potential breaches of fiduciary duty in its transaction with Aurinia, aiming to ensure the protection of all shareholders' rights.
- Cash and Rights Compensation: In this transaction, Kezar shareholders will receive $6.955 in cash per share plus a contingent value right (CVR), which involves potential payments from the clinical development of zetomipzomib and proceeds from collaboration with Everest Medicines, highlighting the complexity and potential value of the deal.
- Internal Conflicts of Interest: Kezar insiders will receive substantial benefits as part of change of control arrangements, raising concerns about whether the board is fulfilling its fiduciary duties to all shareholders, which could impact corporate governance.
- Restrictions on Competing Transactions: The transaction agreement imposes significant penalties on Kezar for accepting competing bids, potentially harming shareholder interests and necessitating further legal scrutiny of the deal.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KZR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KZR
Wall Street analysts forecast KZR stock price to fall
3 Analyst Rating
0 Buy
3 Hold
0 Sell
Hold
Current: 7.360
Low
5.00
Averages
6.00
High
7.00
Current: 7.360
Low
5.00
Averages
6.00
High
7.00
About KZR
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). The Company is focused on the development of zetomipzomib in autoimmune hepatitis, or AIH, a rare, chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage. Its PORTOLA is a placebo-controlled, double-blind Phase IIa clinical trial of zetomipzomib in patients with AIH that were insufficiently responding to standard of care or have relapsed.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Kezar Life Sciences, Inc. (NASDAQ:KZR) regarding its sale to Aurinia Pharmaceuticals Inc. for $6.955 per share in cash and a non-transferable contingent value right, potentially infringing on shareholder rights.
- Merger Transaction Review: Equitable Holdings, Inc. (NYSE:EQH) is merging with Corebridge Financial, Inc., where Equitable shareholders will exchange shares at a ratio of 1.55516, resulting in approximately 49% ownership post-merger, with Halper Sadeh LLC possibly seeking increased consideration.
- Shareholder Rights Protection: Urgent.ly, Inc. (OTC:ULYX) is being sold to Agero, Inc. for $5.50 per share, and Halper Sadeh LLC encourages Urgent.ly shareholders to understand their legal rights and options to ensure their interests are protected in the transaction.
- Legal Fee Arrangement: Halper Sadeh LLC offers legal services on a contingency fee basis, meaning shareholders will not incur out-of-pocket legal fees when addressing any matters, aiming to safeguard investor rights and pursue higher compensation.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) regarding its sale to Biogen Inc. for $41.00 per share in cash and two contingent value rights of $2.00 each, potentially infringing on shareholder rights.
- Shareholder Rights Protection: The firm encourages Apellis shareholders to understand their legal rights and options, emphasizing free consultations to ensure that shareholder interests are protected in the transaction.
- Additional Company Investigations: Centessa Pharmaceuticals plc (NASDAQ:CNTA) is also under scrutiny for its sale to Eli Lilly for $38.00 per share plus a contingent value right of up to $9.00, with Halper Sadeh LLC investigating possible breaches of fiduciary duties.
- Legal Relief Measures: Halper Sadeh LLC represents investors globally, seeking increased consideration, additional disclosures, or other relief to advocate for the rights of affected shareholders.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Kezar Life Sciences, Inc. (NASDAQ:KZR) regarding its sale to Aurinia Pharmaceuticals Inc. for $6.955 per share in cash and a non-transferable contingent value right, potentially infringing on shareholder rights.
- Shareholder Rights Protection: The firm is also scrutinizing Talkspace, Inc. (NASDAQ:TALK) in its sale to Universal Health Services, Inc. for $5.25 per share, aiming to ensure shareholders receive fair terms and necessary disclosures.
- Warner Bros. Transaction Review: Halper Sadeh LLC is examining Warner Bros. Discovery, Inc. (NASDAQ:WBD) in its sale to Paramount Skydance Corporation for $31.00 per share in cash, which may impact shareholder interests and options.
- Legal Fee Arrangement: The firm commits to handling cases on a contingent fee basis, ensuring that affected shareholders do not incur out-of-pocket legal expenses, thereby encouraging more shareholders to engage in protective actions.
See More
Monteverde Law Firm Investigates Multiple Biotech Companies
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the transaction between Kezar Life Sciences, Inc. and Aurinia Pharmaceuticals Inc., with Kezar shareholders expected to receive $6.955 per share in cash and a non-transferable contingent value right, aiming to protect shareholder interests and ensure transaction fairness.
- Centessa Transaction Details: In the deal between Centessa Pharmaceuticals plc and Eli Lilly, Centessa shareholders are anticipated to receive $38.00 per share in cash along with a contingent value right that could yield up to $9.00 based on certain milestones, demonstrating the company's commitment to shareholder value.
- Talkspace Shareholder Rights: In the transaction involving Talkspace, Inc. and Universal Health Services, Inc., Talkspace shareholders will receive $5.25 per share in cash, indicating the deal aims to provide direct cash returns to shareholders and enhance their confidence.
- Warner Bros. Transaction Progress: Warner Bros. Discovery, Inc. is set to receive $31.00 per share in cash and additional compensation based on elapsed time in its deal with Paramount Skydance Corporation, with a shareholder vote scheduled for April 23, 2026, reflecting the company's transparency and the importance of shareholder engagement in mergers.
See More
Investigation Launched into Kezar's Transaction with Aurinia
- Shareholder Rights Investigation: Ademi LLP is investigating Kezar (NASDAQ: KZR) for potential breaches of fiduciary duty in its transaction with Aurinia, aiming to ensure the protection of all shareholders' rights.
- Cash and Rights Compensation: In this transaction, Kezar shareholders will receive $6.955 in cash per share plus a contingent value right (CVR), which involves potential payments from the clinical development of zetomipzomib and proceeds from collaboration with Everest Medicines, highlighting the complexity and potential value of the deal.
- Internal Conflicts of Interest: Kezar insiders will receive substantial benefits as part of change of control arrangements, raising concerns about whether the board is fulfilling its fiduciary duties to all shareholders, which could impact corporate governance.
- Restrictions on Competing Transactions: The transaction agreement imposes significant penalties on Kezar for accepting competing bids, potentially harming shareholder interests and necessitating further legal scrutiny of the deal.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating several companies, including Kezar Life Sciences and National Storage Affiliates Trust, for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder financial interests.
- Kezar Life Transaction Details: Kezar Life Sciences is being sold to Aurinia Pharmaceuticals for $6.955 per share in cash and one non-transferable contingent value right, with terms that may limit superior competing offers, affecting shareholder options.
- Equitable Merger Situation: The merger between Equitable Holdings and Corebridge Financial will allow Equitable shareholders to exchange each share for 1.55516 shares of the combined company's common stock, resulting in shareholders owning approximately 49% of the merged entity, potentially impacting shareholder control.
- Coterra Energy Deal: Coterra Energy is being sold for 0.70 shares of Devon Energy common stock per share, and Halper Sadeh LLC may seek increased consideration and additional disclosures on behalf of shareholders to ensure their rights are protected.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Kezar Life Sciences, Inc. (NASDAQ:KZR) regarding its sale to Aurinia Pharmaceuticals Inc. for $6.955 per share in cash and a non-transferable contingent value right, potentially infringing on shareholder rights.
- Merger Transaction Review: Equitable Holdings, Inc. (NYSE:EQH) is merging with Corebridge Financial, Inc., where Equitable shareholders will exchange shares at a ratio of 1.55516, resulting in approximately 49% ownership post-merger, with Halper Sadeh LLC possibly seeking increased consideration.
- Shareholder Rights Protection: Urgent.ly, Inc. (OTC:ULYX) is being sold to Agero, Inc. for $5.50 per share, and Halper Sadeh LLC encourages Urgent.ly shareholders to understand their legal rights and options to ensure their interests are protected in the transaction.
- Legal Fee Arrangement: Halper Sadeh LLC offers legal services on a contingency fee basis, meaning shareholders will not incur out-of-pocket legal fees when addressing any matters, aiming to safeguard investor rights and pursue higher compensation.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) regarding its sale to Biogen Inc. for $41.00 per share in cash and two contingent value rights of $2.00 each, potentially infringing on shareholder rights.
- Shareholder Rights Protection: The firm encourages Apellis shareholders to understand their legal rights and options, emphasizing free consultations to ensure that shareholder interests are protected in the transaction.
- Additional Company Investigations: Centessa Pharmaceuticals plc (NASDAQ:CNTA) is also under scrutiny for its sale to Eli Lilly for $38.00 per share plus a contingent value right of up to $9.00, with Halper Sadeh LLC investigating possible breaches of fiduciary duties.
- Legal Relief Measures: Halper Sadeh LLC represents investors globally, seeking increased consideration, additional disclosures, or other relief to advocate for the rights of affected shareholders.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Kezar Life Sciences, Inc. (NASDAQ:KZR) regarding its sale to Aurinia Pharmaceuticals Inc. for $6.955 per share in cash and a non-transferable contingent value right, potentially infringing on shareholder rights.
- Shareholder Rights Protection: The firm is also scrutinizing Talkspace, Inc. (NASDAQ:TALK) in its sale to Universal Health Services, Inc. for $5.25 per share, aiming to ensure shareholders receive fair terms and necessary disclosures.
- Warner Bros. Transaction Review: Halper Sadeh LLC is examining Warner Bros. Discovery, Inc. (NASDAQ:WBD) in its sale to Paramount Skydance Corporation for $31.00 per share in cash, which may impact shareholder interests and options.
- Legal Fee Arrangement: The firm commits to handling cases on a contingent fee basis, ensuring that affected shareholders do not incur out-of-pocket legal expenses, thereby encouraging more shareholders to engage in protective actions.
See More
Monteverde Law Firm Investigates Multiple Biotech Companies
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the transaction between Kezar Life Sciences, Inc. and Aurinia Pharmaceuticals Inc., with Kezar shareholders expected to receive $6.955 per share in cash and a non-transferable contingent value right, aiming to protect shareholder interests and ensure transaction fairness.
- Centessa Transaction Details: In the deal between Centessa Pharmaceuticals plc and Eli Lilly, Centessa shareholders are anticipated to receive $38.00 per share in cash along with a contingent value right that could yield up to $9.00 based on certain milestones, demonstrating the company's commitment to shareholder value.
- Talkspace Shareholder Rights: In the transaction involving Talkspace, Inc. and Universal Health Services, Inc., Talkspace shareholders will receive $5.25 per share in cash, indicating the deal aims to provide direct cash returns to shareholders and enhance their confidence.
- Warner Bros. Transaction Progress: Warner Bros. Discovery, Inc. is set to receive $31.00 per share in cash and additional compensation based on elapsed time in its deal with Paramount Skydance Corporation, with a shareholder vote scheduled for April 23, 2026, reflecting the company's transparency and the importance of shareholder engagement in mergers.
See More
Investigation Launched into Kezar's Transaction with Aurinia
- Shareholder Rights Investigation: Ademi LLP is investigating Kezar (NASDAQ: KZR) for potential breaches of fiduciary duty in its transaction with Aurinia, aiming to ensure the protection of all shareholders' rights.
- Cash and Rights Compensation: In this transaction, Kezar shareholders will receive $6.955 in cash per share plus a contingent value right (CVR), which involves potential payments from the clinical development of zetomipzomib and proceeds from collaboration with Everest Medicines, highlighting the complexity and potential value of the deal.
- Internal Conflicts of Interest: Kezar insiders will receive substantial benefits as part of change of control arrangements, raising concerns about whether the board is fulfilling its fiduciary duties to all shareholders, which could impact corporate governance.
- Restrictions on Competing Transactions: The transaction agreement imposes significant penalties on Kezar for accepting competing bids, potentially harming shareholder interests and necessitating further legal scrutiny of the deal.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating several companies, including Kezar Life Sciences and National Storage Affiliates Trust, for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder financial interests.
- Kezar Life Transaction Details: Kezar Life Sciences is being sold to Aurinia Pharmaceuticals for $6.955 per share in cash and one non-transferable contingent value right, with terms that may limit superior competing offers, affecting shareholder options.
- Equitable Merger Situation: The merger between Equitable Holdings and Corebridge Financial will allow Equitable shareholders to exchange each share for 1.55516 shares of the combined company's common stock, resulting in shareholders owning approximately 49% of the merged entity, potentially impacting shareholder control.
- Coterra Energy Deal: Coterra Energy is being sold for 0.70 shares of Devon Energy common stock per share, and Halper Sadeh LLC may seek increased consideration and additional disclosures on behalf of shareholders to ensure their rights are protected.
See More
